Vir Biotechnology (VIR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.47
- EPS estimate
- $0.33
- EPS surprise
- +41.31%
- Revenue surprise
- +75.85%
- Revenue
- $238.9M
- Revenue estimate
- $135.9M
- Reported
- Aug 5, 2026
Vir Biotechnology reported Q2 2026 results on August 5, 2026. It earned $0.47 per share, ahead of the $0.33 estimate by 41.31%. Revenue was $238.9 million against a $135.9 million consensus. A year earlier, in Q2 2025, Vir lost $0.80 per share on revenue of $1.2 million.
The quarter was Vir's first profit in the table since Q3 2022. In between came 14 straight quarterly losses, including $0.85 per share in Q1 2026. Annual losses per share were $4.59 in 2023, $3.82 in 2024 and $3.16 in 2025, on yearly revenue of $86.2 million, $74.3 million and $68.5 million. Quarterly revenue swung widely over that stretch, from $240,000 in Q3 2025 to $64.1 million in Q4 2025. The earliest rows look very different: Vir earned $3.92 per share in Q4 2021 and $3.85 in Q1 2022, on revenue of $812.7 million and $1.2 billion. Over the 20 quarters shown, Vir beat the EPS estimate 9 times.
Q3 results have come out between October 31 and November 5 in each of the past five years. That points to early November 2026 for the next report, which will show whether the profit holds for a second quarter.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.33 | $0.47 | +41.31% | $238.9M | SEC |
| Q1 2026 | May 6, 2026 | −$0.10 | −$0.85 | −790.05% | −$29,000.00 | SEC |
| Q4 2025 | Feb 23, 2026 | −$0.49 | −$0.31 | +36.88% | $64.1M | SEC |
| Q3 2025 | Nov 5, 2025 | −$0.84 | −$1.17 | −38.64% | $240,000.00 | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.72 | −$0.80 | −10.67% | $1.2M | SEC |
| Q1 2025 | May 7, 2025 | −$0.84 | −$0.88 | −5.30% | $3.0M | SEC |
| Q4 2024 | Feb 26, 2025 | −$0.87 | −$0.76 | +12.86% | $12.4M | SEC |
| Q3 2024 | Oct 31, 2024 | −$1.05 | −$1.56 | −48.22% | $2.4M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.90 | −$1.02 | −13.97% | $3.1M | SEC |
| Q1 2024 | May 2, 2024 | −$1.05 | −$0.48 | +54.35% | $56.4M | SEC |
| Q4 2023 | Feb 22, 2024 | −$1.01 | −$0.86 | +14.67% | $16.8M | SEC |
| Q3 2023 | Nov 2, 2023 | −$1.21 | −$1.22 | −1.09% | $2.6M | SEC |
| Q2 2023 | Aug 3, 2023 | −$1.20 | −$1.45 | −20.50% | $3.8M | SEC |
| Q1 2023 | May 4, 2023 | −$0.87 | −$1.06 | −21.20% | $63.0M | SEC |
| Q4 2022 | Feb 23, 2023 | −$0.35 | −$0.76 | −118.71% | $49.4M | SEC |
| Q3 2022 | Nov 3, 2022 | −$0.51 | $1.30 | +355.91% | $374.6M | SEC |
| Q2 2022 | Aug 9, 2022 | $0.33 | −$0.58 | −276.40% | −$40.6M | SEC |
| Q1 2022 | May 5, 2022 | $3.78 | $3.85 | +1.85% | $1.2B | SEC |
| Q4 2021 | Feb 24, 2022 | $2.63 | $3.92 | +49.26% | $812.7M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.05 | $0.82 | +1826.32% | $103.6M | SEC |
Quarterly revenue
Frequently asked questions
When did Vir Biotechnology (VIR) last report earnings?
Vir Biotechnology last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did VIR beat earnings estimates?
Yes. Vir Biotechnology reported EPS of $0.47 for Q2 2026 against a $0.33 estimate — a 41.31% beat.
How much revenue did VIR report last quarter?
Vir Biotechnology reported $238.9M in revenue for Q2 2026, against a consensus estimate of $135.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.